Communiqués Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Temps Différé Nasdaq Autres places de cotation 19:17:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
5,13 ^USD	-0,97 %		+1,37 %	-30,68 %

13/06	Pasithea Therapeutics Corp. annonce la fin du recrutement et l'administration de la première dose de la cohorte 2 suite à la recommandation positive du comité d'évaluation de la sécurité pour PAS-004 dans le cadre de l'essai clinique de phase 1 en cours.	CI
14/05	Pasithea Therapeutics Corp. présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial	13/06	AQ
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting	28/05	AQ
Pasithea Therapeutics : Shareholder Meeting - Form 8-K	14/05	PU
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	29/04	AQ
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	24/04	AQ
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	13/02	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	09/01	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01	AQ
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	02/01	AQ
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	28/12	AQ
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	19/12	AQ
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	11/12	AQ
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	29/11	AQ
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development	29/11	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 51 Integrin for the Treatment of both Sporadic and Familial ALS	10/11	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS	09/11	AQ
Pasithea Therapeutics : Investor Presentation	13/10/23	PU
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer	14/09/23	AQ
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference	07/09/23	AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences that shows an increase in 5 integrin expression in ALS human and mouse brain tissue	02/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Communiqués

Filtres